TargetPro
AI-empowered platform for rapid and precise novel drug target identification.
Executive Summary
TargetPro is an advanced, AI-empowered platform developed by Insilico Medicine specifically for the identification of novel drug targets. It leverages generative artificial intelligence to accelerate and enhance the early stages of drug discovery, aiming to extend healthy, productive longevity by transforming traditional research and development processes. The platform is designed to predict and validate potential drug targets with high precision. Its capabilities have been demonstrated through impressive metrics, with predicted novel targets showing 95.7% structure availability, 86.5% druggability, and 46% repurposing potential. TargetPro is a key component of Insilico Medicine's broader Pharma.AI platform, which integrates various AI modules like PandaOmics for comprehensive target discovery and disease biology insights, providing an end-to-end solution for pharmaceutical research.
Use Cases
- Identify novel drug targets for specific diseases and therapeutic areas.
- Prioritize potential targets based on predicted druggability and structural availability.
- Discover repurposing potential for existing drugs or compounds against new targets.
- Accelerate early-stage drug discovery pipelines by streamlining target identification.
- Generate comprehensive gene-disease reports to inform target investigation.
Features
Visibility
- Interactive Target Dashboard: Visualize and explore identified novel drug targets with interactive filters and detailed views.
Intelligence
- Novel Target Prediction: AI-driven identification of previously unknown or under-explored drug targets.
- Druggability Assessment: Evaluates the likelihood of a predicted target being modulated by a small molecule or biologic.
- Structure Availability Analysis: Assesses the availability of structural data for predicted targets, crucial for drug design.
- Repurposing Potential Identification: Identifies existing drugs or compounds that could be repurposed for novel targets or indications.
- Gene-Disease Report Generation: Creates comprehensive reports linking genes to diseases, aiding in target investigation.
Technical Specifications
- Deployment
- SaaS
AI/ML Stack
- Generative AI
- Machine Learning
Pricing
- Model
- Subscription-based
- Starting Price
- Contact sales
- Target Customer
- Mid-Market,Enterprise
- Contract Type
- Annual
About Insilico Medicine
Insilico Medicine is a clinical-stage biotechnology company that leverages artificial intelligence and deep learning to accelerate drug discovery and development. The company focuses on therapeutic solutions for cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions, utilizing its proprietary Pharma.AI platform to discover novel targets, design new molecules, and advance candidates into human clinical trials.